FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288060751> ?p ?o ?g. }

• W4288060751 endingPage "1461" @default.
• W4288060751 startingPage "1461" @default.
• W4288060751 abstract "Vascular endothelial cells are crucial mediators of inflammation during infectious diseases, due to their ability to produce lipid-based inflammatory mediators and facilitate leukocyte migration and translocation to infected tissues. Mastitis is the costliest infectious disease in North America, with over two billion dollars in annual costs due to loss of milk production, medical treatment, and potential loss of the animal. Infections caused by coliform bacteria are particularly deleterious, causing a negative impact on cow well-being and a high mortality rate. Dysfunction and breakdown of the endothelial barrier is a key part of the pathology of coliform mastitis. The endocannabinoid system (ECS), shown to modulate inflammatory responses of vascular endothelial cells in humans and rodents, may be a novel target for inflammatory modulation in dairy cows. The endocannabinoid (EC) arachidonoylethanolamide (AEA) is a potent anti- or pro-inflammatory mediator in endothelial cells, depending on location, timing, and concentration. We hypothesized that elevated AEA during LPS challenge will impair endothelial barrier integrity via increased production of reactive oxygen species (ROS) and activation of apoptotic pathways. Challenge of bovine aortic endothelial cells (BAEC) with 25 ng/mL lipopolysaccharide (LPS) for 8 h induced AEA synthesis, increased expression of cannabinoid receptor 1 and 2 (CB1/2) and the AEA synthesizing enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), while decreasing gene expression of the AEA degradation enzyme fatty acid amide hydrolase (FAAH). Trans endothelial resistance (TER), measured through electrical resistance across the monolayer, increased 2 h after 0.5 µM AEA treatment and decreased with 5 µM AEA, compared to LPS alone. Addition of AEA to BAEC challenged with LPS induced mitochondrial dysfunction via increased ROS production, cytochrome-C release, and activation of caspase 3/7. Antagonism of CB1 by 1 µM AM251 ameliorated AEA induced ROS production and cytochrome-C release. Addition of AM251 also eliminated 2 h TER increase and improved TER following 5 µM AEA. Doses of 0.5, 1, and 5 µM AEA delayed endothelial barrier recovery, which was eliminated by the addition of AM251. Mitochondrial dysfunction and activation of apoptotic pathways in response to AEA treatment during LPS challenge of BAEC may act to delay inflammatory resolution and contribute to endothelial dysfunction." @default.
• W4288060751 created "2022-07-28" @default.
• W4288060751 creator A5020672736 @default.
• W4288060751 creator A5052932049 @default.
• W4288060751 creator A5060914076 @default.
• W4288060751 date "2022-07-27" @default.
• W4288060751 modified "2023-09-27" @default.
• W4288060751 title "Anandamide Alters Barrier Integrity of Bovine Vascular Endothelial Cells during Endotoxin Challenge" @default.
• W4288060751 cites W1578641739 @default.
• W4288060751 cites W1844376968 @default.
• W4288060751 cites W1981629743 @default.
• W4288060751 cites W1990144502 @default.
• W4288060751 cites W2011954953 @default.
• W4288060751 cites W2028497968 @default.
• W4288060751 cites W2032128276 @default.
• W4288060751 cites W2054655581 @default.
• W4288060751 cites W2109154570 @default.
• W4288060751 cites W2114703922 @default.
• W4288060751 cites W2178225787 @default.
• W4288060751 cites W2249002575 @default.
• W4288060751 cites W2271361058 @default.
• W4288060751 cites W2336815228 @default.
• W4288060751 cites W2521788301 @default.
• W4288060751 cites W2530536710 @default.
• W4288060751 cites W2770576692 @default.
• W4288060751 cites W2792867168 @default.
• W4288060751 cites W2918451382 @default.
• W4288060751 cites W2947249851 @default.
• W4288060751 cites W2948000217 @default.
• W4288060751 cites W3035159983 @default.
• W4288060751 cites W3084232008 @default.
• W4288060751 cites W3142402500 @default.
• W4288060751 cites W3164785214 @default.
• W4288060751 cites W3165547817 @default.
• W4288060751 cites W4225125658 @default.
• W4288060751 cites W4226017576 @default.
• W4288060751 doi "https://doi.org/10.3390/antiox11081461" @default.
• W4288060751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36009180" @default.
• W4288060751 hasPublicationYear "2022" @default.
• W4288060751 type Work @default.
• W4288060751 citedByCount "0" @default.
• W4288060751 crossrefType "journal-article" @default.
• W4288060751 hasAuthorship W4288060751A5020672736 @default.
• W4288060751 hasAuthorship W4288060751A5052932049 @default.
• W4288060751 hasAuthorship W4288060751A5060914076 @default.
• W4288060751 hasBestOaLocation W42880607511 @default.
• W4288060751 hasConcept C123012128 @default.
• W4288060751 hasConcept C134018914 @default.
• W4288060751 hasConcept C148001335 @default.
• W4288060751 hasConcept C170493617 @default.
• W4288060751 hasConcept C180899940 @default.
• W4288060751 hasConcept C185592680 @default.
• W4288060751 hasConcept C202751555 @default.
• W4288060751 hasConcept C203014093 @default.
• W4288060751 hasConcept C2776914184 @default.
• W4288060751 hasConcept C2778754761 @default.
• W4288060751 hasConcept C2778938600 @default.
• W4288060751 hasConcept C2779783865 @default.
• W4288060751 hasConcept C2780972559 @default.
• W4288060751 hasConcept C2781144285 @default.
• W4288060751 hasConcept C46721173 @default.
• W4288060751 hasConcept C55493867 @default.
• W4288060751 hasConcept C86803240 @default.
• W4288060751 hasConcept C98274493 @default.
• W4288060751 hasConceptScore W4288060751C123012128 @default.
• W4288060751 hasConceptScore W4288060751C134018914 @default.
• W4288060751 hasConceptScore W4288060751C148001335 @default.
• W4288060751 hasConceptScore W4288060751C170493617 @default.
• W4288060751 hasConceptScore W4288060751C180899940 @default.
• W4288060751 hasConceptScore W4288060751C185592680 @default.
• W4288060751 hasConceptScore W4288060751C202751555 @default.
• W4288060751 hasConceptScore W4288060751C203014093 @default.
• W4288060751 hasConceptScore W4288060751C2776914184 @default.
• W4288060751 hasConceptScore W4288060751C2778754761 @default.
• W4288060751 hasConceptScore W4288060751C2778938600 @default.
• W4288060751 hasConceptScore W4288060751C2779783865 @default.
• W4288060751 hasConceptScore W4288060751C2780972559 @default.
• W4288060751 hasConceptScore W4288060751C2781144285 @default.
• W4288060751 hasConceptScore W4288060751C46721173 @default.
• W4288060751 hasConceptScore W4288060751C55493867 @default.
• W4288060751 hasConceptScore W4288060751C86803240 @default.
• W4288060751 hasConceptScore W4288060751C98274493 @default.
• W4288060751 hasIssue "8" @default.
• W4288060751 hasLocation W42880607511 @default.
• W4288060751 hasLocation W42880607512 @default.
• W4288060751 hasLocation W42880607513 @default.
• W4288060751 hasLocation W42880607514 @default.
• W4288060751 hasOpenAccess W4288060751 @default.
• W4288060751 hasPrimaryLocation W42880607511 @default.
• W4288060751 hasRelatedWork W1531994734 @default.
• W4288060751 hasRelatedWork W1596886225 @default.
• W4288060751 hasRelatedWork W1996263740 @default.
• W4288060751 hasRelatedWork W2020846861 @default.
• W4288060751 hasRelatedWork W2034673751 @default.
• W4288060751 hasRelatedWork W2073287729 @default.
• W4288060751 hasRelatedWork W2081432108 @default.
• W4288060751 hasRelatedWork W2087250130 @default.
• W4288060751 hasRelatedWork W2386730103 @default.

• next